Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|16|30|3919-3930

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.16, Iss.30, 2009-01, pp. : 3919-3930

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC)

By Blumenschein George  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1802-1811

Springer Publishing Company

Access to resources Recommend Favorite

The Role of Pemetrexed Combined with Targeted Agents for Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 2-11

Bentham Science Publishers

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer

By Dancey Janet E.  

Drugs, Vol. 67, Iss. 8, 2007-01 ,pp. : 1125-1138

Adis International

Access to resources Recommend Favorite

Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 15, Iss. 14, 2014-01 ,pp. : 1263-1272

Bentham Science Publishers

Access to resources Recommend Favorite

Thymidylate synthase inhibitors for non-small cell lung cancer

By Galvani Elena   Peters Godefridus J   Giovannetti Elisa  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 10, 2011-10 ,pp. : 1343-1356

Informa Healthcare

Access to resources Recommend Favorite